New York, Jan 10, 2026, 16:37 EST — The market is closed.
On Friday, Bernstein lifted its price target for Intuitive Surgical from $700 to $740, maintaining an Outperform rating. The move signals strong confidence as healthcare investors brace for a hectic period. (TipRanks)
Intuitive Surgical shares ended Friday up 0.2%, closing at $586.24. During the day, the stock fluctuated between $579.62 and $589.58. Its 52-week range stands at $425 to $616, per Stock Analysis. (StockAnalysis)
Why it matters now: investors are focused on the J.P. Morgan Healthcare Conference, set for Jan. 12-15 in San Francisco, while also waiting on the company’s next public update. Intuitive plans to present on Jan. 14 at 9:00 a.m. PST and has scheduled its fourth-quarter 2025 earnings call for Jan. 22 at 1:30 p.m. PST. (JPMorgan)
Bernstein’s wider take on medtech sheds light on the current landscape. The firm noted its large-cap U.S. medtech coverage rose roughly 5% in 2025 (equal weight), trailing the S&P 500’s 16% surge. It’s betting on a bounce back in 2026, fueled by stronger procedure growth and fresh product cycles. (Investing)
Bernstein analyst Lee Hambright called the sector “poised for a rebound” in his 2026 outlook comments. (Streetinsider)
On Friday, Goldman Sachs raised its price target for Intuitive Surgical to $714 from $621, maintaining a Buy rating. The firm noted that 2026 might see a shift back to a market where organic growth influences relative valuation, following a year marked by a disconnect between fundamentals and share performance. (TipRanks)
On Thursday, BTIG bumped its target price to $616 from $589, maintaining a Buy rating. The firm highlighted a stronger earnings boost from the da Vinci 5 (“Dv5”) launch than previously anticipated. BTIG noted that Dv5’s impact isn’t just about higher average selling prices per system; the installed base also generates ongoing revenue from instruments and accessories tied to procedure volume. They estimate Dv5 could drive roughly 25% of expected fiscal 2026 revenue growth and about 35% in fiscal 2027. (TipRanks)
This detail is key for Intuitive since every new system usually drives follow-up demand for related tools and accessories. Traders care less about the number of robots shipped and more about how quickly they’re put to work.
Technical levels are also key here. Friday’s intraday peak hit around $590, with the 52-week high of $616 standing as the next target if momentum pushes through during the conference week.
Still, the setup works both ways. Shares hover close to last year’s peak, so any hint of slower procedure growth, hospital capital spending delays, or a bumpy launch of the new platform could sour sentiment fast.
Intuitive is set to present at the J.P. Morgan Healthcare Conference on Jan. 14. Investors will be watching closely for news on da Vinci 5 adoption, shifts in procedure volumes, and a preview of what management might reveal during the Jan. 22 earnings call.
